The recent approval of both pembrolizumab and atezolizumab in combination with standard chemotherapy for PD-L1 positive, metastatic TNBC represents an important step forward for the use of immune checkpoint inhibitors (ICB) in BC [46,47]. The gene discussed is CD274; the disease is breast cancer.